Evidence map›Paper›PMID 41168765›Full record

Observational studyBMC musculoskeletal disorders2025

Treatment with denosumab reduces second hip fracture risk in elderly patients with osteoporotic femoral neck fractures.

Yuzhu Wang, Kunming Pan, Xiaoyu Li, Qianzhou Lv, Yunchao Shao, Lu Cao

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuzhu Wang *Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Kunming Pan *Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiaoyu LiDepartment of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Qianzhou LvDepartment of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Yunchao ShaoDepartment of Orthopaedic Surgery, Zhongshan Hospital, Institute of Bone and Joint Diseases, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China. shao.yunchao@zs-hospital.sh.cn.
Lu CaoDepartment of Orthopaedic Surgery, Zhongshan Hospital, Institute of Bone and Joint Diseases, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China. cao.lu@zs-hospital.sh.cn.

Funding

the National Key Research and Development Program of China 2024YFC3044700the Science and Technology Innovation Action Program of the Shanghai Science and Technology Commission 23ZR1480300
6 · The paper itself

Abstract

backgroundThe issue of second hip fracture following surgery for a hip fracture has recently been the focus of increased research attention. The purpose of our study was to evaluate the effect of denosumab on the risk of second hip fracture following first hip fracture surgery in the elderly Chinese population.

methodsThis was a retrospective observational study in which patients aged 65 years and older suffering from osteoporotic femoral neck fractures between January 1, 2020 and December 31, 2021 were enrolled. The patients were divided into two groups: denosumab group and control group. Propensity score matching (PSM) was performed to adjust between-group differences. Second hip fracture was defined as the time to the first occurrence following first hip fracture.

resultsA total of 259 patients were included in the analysis. After PSM, the risk of second hip fracture was significantly reduced in the denosumab group when compared with that in the control group (8.8% vs. 29.7%, hazard ratio (HR) = 0.29, 95%CI = 0.13-0.64, P = 0.001). The incidence of second hip fracture was significantly lower in female patients and patients aged 65-84 years in the denosumab group than that in the control group (5.3% vs. 29.8%, HR = 0.29, 95%CI = 0.13-0.68, P = 0.002; 6.2% vs. 22.8%, HR = 0.24, 95%CI = 0.08-0.74, P = 0.007; respectively).

conclusionsDenosumab reduced the risk of second hip fracture in elderly patients, with this reduction being especially marked in female patients and those aged 65-84 years. Patients who received denosumab following their first hip fracture had a lower incidence of second hip fractures, thus emphasizing the importance of the prompt initiation of antiosteoporosis treatment in elderly patients following osteoporotic hip fracture.

Indexed as

Bone Density Conservation AgentsDenosumabFemoral Neck FracturesHip FracturesOsteoporotic FracturesAgedAged, 80 and overFemaleHumansIncidenceMaleProximal Femoral FracturesRetrospective StudiesRisk FactorsBone Density Conservation AgentsDenosumabDenosumabElderly patientsFemoral neck fractureOsteoporotic fractureSecond hip fracture

Identifiers

PMID41168765
PMCPMC12573882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.